{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:40:09Z","timestamp":1792309209908,"version":"4.4.0"},"reference-count":29,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"DOI":"10.1080\/14656566.2026.2750247","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:59:39Z","timestamp":1791971979000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal stromal tumors: can we do better than sunitinib in the second line?"],"prefix":"10.1080","author":[{"given":"Piotr","family":"Rutkowski","sequence":"first","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Klimczak","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2015.10.031"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60780-6"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69446-4"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61857-1"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30168-6"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30269-2"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.005"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0389-6"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.7461"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2051-5"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00294"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02734-5"},{"key":"e_1_3_4_17_1","volume-title":"European Medicines Agency. Qinlock (ripretinib): summary of product characteristics. Amsterdam (The Netherlands): European Medicines Agency;","year":"2023","unstructured":"European Medicines Agency. Qinlock (ripretinib): summary of product characteristics. Amsterdam (The Netherlands): European Medicines Agency;2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/qinlock-epar-product-information_en.pdf"},{"key":"e_1_3_4_18_1","volume-title":"European Medicines Agency. Sutent (sunitinib): summary of product characteristics. Amsterdam (The Netherlands): European Medicines Agency;","year":"2021","unstructured":"European Medicines Agency. Sutent (sunitinib): summary of product characteristics. Amsterdam (The Netherlands): European Medicines Agency;2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sutent-epar-product-information_en.pdf"},{"key":"e_1_3_4_19_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): gastrointestinal stromal tumors. Version 1.2024. Plymouth Meeting (PA): NCCN; 2024 [cited 2026 Sep 14]. Available from: https:\/\/www.nccn.org"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2376521"},{"issue":"6","key":"e_1_3_4_21_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.5603\/OCP.2018.0053","article-title":"Gastrointestinal stromal tumours (GIST) \u2014 2018","volume":"14","author":"Rutkowski P","year":"2018","unstructured":"Rutkowski P, Szumera-Cie\u0107kiewicz A. Gastrointestinal stromal tumours (GIST) \u2014 2018. Oncol Clin Pract. 2018;14(6):399\u2013407. Available from: https:\/\/journals.viamedica.pl\/oncology_in_clinical_practice\/article\/view\/59630","journal-title":"Oncol Clin Pract"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.11518"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.11533"},{"key":"e_1_3_4_24_1","unstructured":"Cogent Biosciences Inc. Cogent Biosciences announces submission of new drug application for bezuclastinib in gastrointestinal stromal tumors (GIST). [Press release]. 2026 Apr 1 [cited 2026 Sep 14]. Available from: https:\/\/www.cogentbio.com"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.11501"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115565"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13674"},{"key":"e_1_3_4_28_1","unstructured":"European Medicines Agency. Ayvakyt (avapritinib): summary of product characteristics. Amsterdam (The Netherlands): European Medicines Agency;2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ayvakyt-epar-product-information_en.pdf"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00217"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200001000-00008"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.61"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2750247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2750247","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2750247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:01:45Z","timestamp":1792306905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2750247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":29,"alternative-id":["10.1080\/14656566.2026.2750247"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2750247","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}